Mid-Sized Bard Delivers Solid Growth In Device Landscape Of Giants, Infants
This article was originally published in The Gray Sheet
Executive Summary
Bard aims to rely on execution in niche areas where it can comfortably sustain market leadership to deliver sustainable double-digit revenue growth, according to President & CEO Tim Ring
You may also be interested in...
Bard’s Oncology Device Success Compensates For Weakened Vascular Sales
Bard's Power PICC and Triple Lumen PICC peripherally inserted central catheters helped propel the firm's oncology line during the second quarter
Bard’s Oncology Device Success Compensates For Weakened Vascular Sales
Bard's Power PICC and Triple Lumen PICC peripherally inserted central catheters helped propel the firm's oncology line during the second quarter
Bard Expects Coated Endotracheal Tube In 2007, Recovery Aids Q1 Growth
Bard will file a 510(k) for its anti-infection endotracheal tube in mid-2006 after conducting a 60-site, 1,700-patient clinical trial